# Geoffrey Liu
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/geoffrey-liu/
## Facts
| Field | Value |
| --- | --- |
| Citations | 49,003 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 103 |
| i10-index | 591 |
| Last Known Institution | University Health Network |
| OpenAlex ID | https://openalex.org/A5100647137 |
| ORCID iD | https://orcid.org/0000-0002-2603-7296 |
| Works | 1,686 |
## Researcher papers
- [Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome](https://scholariq.org/papers/erlotinib-in-lung-cancer-molecular-and-clinical-predictors-of-outcome/)
- [Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/ceritinib-in-i-alk-i-rearranged-non-small-cell-lung-cancer/)
- [A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25](https://scholariq.org/papers/a-susceptibility-locus-for-lung-cancer-maps-to-nicotinic-acetylcholine-receptor/)
- [First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer](https://scholariq.org/papers/first-line-lorlatinib-or-crizotinib-in-advanced-i-alk-i-positive-lung-cancer/)
- [Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes](https://scholariq.org/papers/large-scale-association-analysis-identifies-new-lung-cancer-susceptibility-loci/)
- [Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study](https://scholariq.org/papers/obesity-metabolic-factors-and-risk-of-different-histological-types-of-lung/)
- [Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/ceritinib-versus-chemotherapy-in-patients-with-alk-rearranged-non-small-cell/)
- [Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial](https://scholariq.org/papers/activity-and-safety-of-ceritinib-in-patients-with-alk-rearranged-non-small-cell/)
- [Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer](https://scholariq.org/papers/genome-wide-association-analyses-identify-new-susceptibility-loci-for-oral/)
- [Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-versus-docetaxel-for-previously-treated-advanced-or/)
- [Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk.](https://scholariq.org/papers/polymorphisms-in-the-dna-repair-genes-xrcc1-and-ercc2-smoking-and-lung-cancer/)
- [Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus](https://scholariq.org/papers/common-variants-at-the-mhc-locus-and-at-chromosome-16q24-1-predispose-to-barrett/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
## Researcher university
- [University Health Network](https://scholariq.org/institutions/university-health-network/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.